European Commission funds NUDZ·$0.22mLilly buys AtaiBeckley·$3.8bnOtsuka buys Transcend·$1.2bnPfizer buys Metsera·no dollar priceAbbVie buys Gilgamesh·$1.2bnatai buys Beckley Psytech·no dollar priceAbbVie takes an option on Gilgamesh·$2bnEuropean Commission funds NUDZ·$0.22mLilly buys AtaiBeckley·$3.8bnOtsuka buys Transcend·$1.2bnPfizer buys Metsera·no dollar priceAbbVie buys Gilgamesh·$1.2bnatai buys Beckley Psytech·no dollar priceAbbVie takes an option on Gilgamesh·$2bnEuropean Commission funds NUDZ·$0.22mLilly buys AtaiBeckley·$3.8bnOtsuka buys Transcend·$1.2bnPfizer buys Metsera·no dollar priceAbbVie buys Gilgamesh·$1.2bnatai buys Beckley Psytech·no dollar priceAbbVie takes an option on Gilgamesh·$2bn
Next issueIssue 23 · Tue 17 Nov 

Assets

COMP360

Compass Pathways

Molecule class
synthetic psilocybin (company description)
Mechanism
Not independently verified.
Phase
Phase 3 complete (COMP005, COMP006); rolling NDA, final submission "will be filed in the next two weeks" (Q3 release, 2026-11-03)
Indication
treatment-resistant depression; PTSD programme separate
Sponsor geography
UK
Next catalyst
Final rolling NDA submission, by 2026-11-17
Partner
US Department of Veterans Affairs (PIVOT study, drug donation and training support only)
IP status
Not checked. Recorded as unchecked rather than left blank.

The catalyst above is recorded as guided, not verified. It is this publication's reading of the company's guidance, not a date the company has published.

sec.govregistryverified 2026-11-07

Registered trials

  • NCT05624268ClinicalTrials.gov

    PHASE3 · Treatment Resistant Depression · COMPLETED · United States

    clinicaltrials.govctgov registryverified 2026-08-31

  • NCT05711940ClinicalTrials.gov

    PHASE3 · Treatment Resistant Depression · ACTIVE_NOT_RECRUITING · Canada, Czechia, Denmark, France, Germany, Ireland, Netherlands, Poland, Spain, Sweden, United Kingdom, United States

    clinicaltrials.govctgov registryverified 2026-08-31

  • 2023-505268-12-00CTIS

    Therapeutic confirmatory (Phase III) · Treatment-resistant depression · Authorised · Czechia, Denmark, France, Germany, Ireland, Netherlands, Poland, Spain, Sweden

    euclinicaltrials.euctis registryverified 2026-08-31

  • NCT07570654ClinicalTrials.gov

    PHASE2;PHASE3 · PTSD - Post Traumatic Stress Disorder;PTSD;PTSD Symptoms;PTSD, Post Traumatic Stress Disorder · RECRUITING · Canada, United States

    clinicaltrials.govctgov registryverified 2026-11-07

In the briefing

Issues tagged COMPASS, the owner of this asset.

Record history